ArticleReproductive toxicology (Elmsford, N.Y.)2026
Maternal mycoestrogen exposure in relation to timing of birth and placental corticotropin releasing hormone concentrations in a U.S. pregnancy cohort.
Article in Reproductive toxicology (Elmsford, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Zearalenone (ZEN) is a mycotoxin that widely contaminates human food supplies. In animal models, exposure to ZEN has extensive impacts on reproduction and pregnancy including contributing to early parturition. Here, we translate that research to humans by examining gestational exposure to ZEN in relation to the timing of birth and placental corticotropin releasing hormone (pCRH), a hormone that regulates the timing of parturition. Utilizing data from a pregnancy cohort (UPSIDE; Rochester, NY; n = 299), we investigated exposure to ZEN and its metabolites in relation to: 1) gestational age at birth; and 2) pCRH across pregnancy. Adjusted linear regression models were fitted to examine gestational age at birth and pCRH in relation to three maternal urinary mycoestrogen measures in each trimester: (1) ZEN; (2) its metabolite, α-zearalenol (aZOL); and (3) the sum of ZEN and its five metabolites (∑mycoestrogens). For models examining pCRH, we additionally fitted linear mixed effects models to account for repeated measures. All models were refitted stratified by fetal sex. Mycoestrogens were detected in over 90% of samples in each trimester. Sex-stratified analyses showed distinct sex differences in trimester 2 in relation to exposure, with higher gestational age at birth in males (β:2.35 days, 95%CI:0.14, 4.56) and lower gestational age at birth in females (β:-1.70 days, 95%CI:-3.35, -0.07). In linear mixed effects models examining pCRH, ZEN was positively associated with pCRH concentrations: ZEN (%Δ:5.17, 95%CI:1.09, 9.36). Mycoestrogen exposure may be associated with sex-specific changes in gestational age at birth and higher pCRH, a risk factor for preterm birth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.